166 related articles for article (PubMed ID: 19138933)
1. Aberrant crypt foci in the adenoma prevention with celecoxib trial.
Cho NL; Redston M; Zauber AG; Carothers AM; Hornick J; Wilton A; Sontag S; Nishioka N; Giardiello FM; Saltzman JR; Gostout C; Eagle CJ; Hawk ET; Bertagnolli MM
Cancer Prev Res (Phila); 2008 Jun; 1(1):21-31. PubMed ID: 19138933
[TBL] [Abstract][Full Text] [Related]
2. Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".
Stevens RG; Pretlow TP; Hurlstone DP; Giardina C; Rosenberg DW
Cancer Prev Res (Phila); 2008 Aug; 1(3):215-6; author reply 216. PubMed ID: 19138959
[No Abstract] [Full Text] [Related]
3. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
[TBL] [Abstract][Full Text] [Related]
5. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
[TBL] [Abstract][Full Text] [Related]
6. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.
Hurlstone DP; Karajeh M; Sanders DS; Drew SK; Cross SS
Am J Gastroenterol; 2005 Jun; 100(6):1283-9. PubMed ID: 15929758
[TBL] [Abstract][Full Text] [Related]
7. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.
Bertagnolli MM; Hsu M; Hawk ET; Eagle CJ; Zauber AG;
Cancer Prev Res (Phila); 2010 May; 3(5):588-96. PubMed ID: 20403998
[TBL] [Abstract][Full Text] [Related]
8. [Mutations of APC and K-ras gene in aberrant crypt foci from human colon].
Yuan P; Sun M; Zhang J; Zhu X; Shi D
Zhonghua Bing Li Xue Za Zhi; 2001 Feb; 30(1):35-8. PubMed ID: 11866955
[TBL] [Abstract][Full Text] [Related]
9. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Breazna A; Kim K; Tang J; Rosenstein RB; Umar A; Bagheri D; Collins NT; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Hawk ET;
Cancer Prev Res (Phila); 2009 Apr; 2(4):310-21. PubMed ID: 19336730
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
11. Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis.
Takayama T; Ohi M; Hayashi T; Miyanishi K; Nobuoka A; Nakajima T; Satoh T; Takimoto R; Kato J; Sakamaki S; Niitsu Y
Gastroenterology; 2001 Sep; 121(3):599-611. PubMed ID: 11522744
[TBL] [Abstract][Full Text] [Related]
12. The natural history of aberrant crypt foci.
Schoen RE; Mutch M; Rall C; Dry SM; Seligson D; Umar A; Pinsky P
Gastrointest Endosc; 2008 Jun; 67(7):1097-102. PubMed ID: 18178205
[TBL] [Abstract][Full Text] [Related]
13. Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans?
Gupta AK; Schoen RE
Curr Opin Gastroenterol; 2009 Jan; 25(1):59-65. PubMed ID: 19114775
[TBL] [Abstract][Full Text] [Related]
14. Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease.
Bouzourene H; Chaubert P; Seelentag W; Bosman FT; Saraga E
Hum Pathol; 1999 Jan; 30(1):66-71. PubMed ID: 9923929
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia.
Sinicrope FA; Viggiano TR; Buttar NS; Song LMWK; Schroeder KW; Kraichely RE; Larson MV; Sedlack RE; Kisiel JB; Gostout CJ; Kalaiger AM; Patai ÁV; Della'Zanna G; Umar A; Limburg PJ; Meyers JP; Foster NR; Yang CS; Sontag S
Cancer Prev Res (Phila); 2021 May; 14(5):573-580. PubMed ID: 33648940
[TBL] [Abstract][Full Text] [Related]
16. Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention.
Thompson P; Roe DJ; Fales L; Buckmeier J; Wang F; Hamilton SR; Bhattacharyya A; Green S; Hsu CH; Chow HH; Ahnen DJ; Boland CR; Heigh RI; Fay DE; Martinez ME; Jacobs E; Ashbeck EL; Alberts DS; Lance P
Cancer Prev Res (Phila); 2012 Dec; 5(12):1381-93. PubMed ID: 23060037
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib for the prevention of sporadic colorectal adenomas.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
[TBL] [Abstract][Full Text] [Related]
18. Aberrant crypt foci: detection, gene abnormalities, and clinical usefulness.
Takayama T; Miyanishi K; Hayashi T; Kukitsu T; Takanashi K; Ishiwatari H; Kogawa T; Abe T; Niitsu Y
Clin Gastroenterol Hepatol; 2005 Jul; 3(7 Suppl 1):S42-5. PubMed ID: 16012995
[TBL] [Abstract][Full Text] [Related]
19. Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse.
Song J; Medline A; Mason JB; Gallinger S; Kim YI
Cancer Res; 2000 Oct; 60(19):5434-40. PubMed ID: 11034085
[TBL] [Abstract][Full Text] [Related]
20. Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention.
Lance P; Hamilton SR
Cancer Prev Res (Phila); 2008 Jun; 1(1):4-8. PubMed ID: 19138929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
